A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Apremilast (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- 11 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 11 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 11 Apr 2017 Status changed from recruiting to active, no longer recruiting.